Next 10 |
home / stock / evax / evax articles
The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI ...
COPENHAGEN, Denmark, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio ...
COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio ...
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected ...
COPENHAGEN, Denmark, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio ...
Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported fourth-quarter ...
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Wednesday. The Dow traded down 0.05% to 37,886.62 whi...
Evaxion Biotech A/S (NASDAQ:EVAX) announces an expanded commitment to developing tailored cancer vaccines by targeting a novel category of AI-...
Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $1...
News, Short Squeeze, Breakout and More Instantly...
Evaxion Biotech A/S Company Name:
EVAX Stock Symbol:
NASDAQ Market:
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing Favorable safety profile confirmed Trial on track for one-year clinical efficacy readout in Q3 2024 COPENHAGEN, Denmark, April 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S ...
Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infections The vaccine antigens significantly protected large, non-rodent animals against surgical site infections, indicating promisi...
Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named endogenous retroviruses (ERVs), broadening the potential of cancer vaccines. Successful completi...